# Precision Cancer Prevention and Treatment

Leveraging Innovations in Molecular Medicine to Improve Early Detection, Prevent Recurrence, and Optimize Outcome







### **Overview**

This joint symposium, dedicated to **Precision Cancer Prevention** and **Treatment**, features international-recognized faculty and opinion leaders from Memorial Sloan Kettering and Hackensack Meridian Health. Molecular innovations will be highlighted, including how these can be applied across the care continuum and integrated with clinico-pathologic and lifestyle factors to prevent cancer in the broadest sense:

- by facilitating earlier diagnosis at a more treatable stage;
- · guiding risk stratification; and
- preventing relapse through early and targeted precision interventions for molecularly-identified, minimal residual disease.

The full-day program will be **keynotes**, **lectures** and **panel discussions** engaging on topics that include disease prevention at the molecular level, immunobiomarkers, liquid biopsies in oncology, parallel tumor normal sequencing to inform diagnosis and management, molecular medicine and diverse populations, using "big-data" studies to better understand the impact of molecular medicine, and the medical implications of clonal hematopoiesis of indeterminant potential. There will be **ample opportunity to interact** with program faculty and attendees.

#### **Who Should Attend**

This symposium is intended for physicians, advanced practice providers, nurses, researchers, and trainees interested in molecular medicine, precision cancer prevention, and targeted treatments.



#### **Symposium Location**

This symposium is hosted by the **Memorial Sloan Kettering** - **Hackensack Meridian Health Partnership** will be held at the Hackensack Meridian Health School of Medicine.

Hackensack Meridian Health School of Medicine\* 123 Metro Boulevard Nutley, NJ 07110

Please note that this course will only be offered as a live in-person option; **no live stream or recording will be available**.

In 2016, Memorial Sloan Kettering Cancer Center and Hackensack Meridian Health formed a clinical partnership dedicated to keeping communities across New Jersey healthy.

Hackensack Meridian Health's integrated health care network and expansive reach coupled with Memorial Sloan Kettering's specialized cancer expertise enable us to provide the best prevention tools and screenings. We know that early detection is the best way to prevent, treat, and cure cancer.

## **Faculty**

#### **MSK-HMH Partnership Executive Leaders**



Andre Goy, MD

Physician-in-Chief, Hackensack Meridian Health
Oncology Care Transformation Services;
Chairman & Chief Physician Officer, John Theurer Cancer Center
at Hackensack University Medical Center;
Lymphoma Division Chief, John Theurer Cancer Center



**David Pfister, MD**Chief, Head and Neck Oncology Service; Associate Deputy Physician-in-Chief, Strategic Partnerships
Memorial Sloan Kettering Cancer Center

#### **Guest Faculty**

Maher Albitar, MD Chief Executive Officer; Chief Medical Officer Genomic Testing Cooperative Irvine, CA

#### John Marshall, MD

Chief, Hematology and Oncology; Professor of Medicine and Oncology; Director, Otto J Ruesch Center for the Cure of Gastrointestinal Cancers Georgetown Lombardi Comprehensive Cancer Center Washington DC

#### **Hackensack Meridian Health Faculty**

#### David (Kar Fai) Chow, MD

Medical Director, HMH Biorepository

#### Martin Gutierrez, MD

Director, Drug Discovery; Chief, Thoracic Oncology

#### Andrew Ip, MD

Director, Division of Outcomes and Value Research

#### Jamie Koprivnikar, MD

Attending, Hematology Oncology

#### **Patient Speaker**

Renee Al-Sarraf, DVM

#### David C. Leopold, MD, DABFM, DABOIM

Medical Director, Integrative Health and Medicine

#### Kash Patel, MD

Executive Vice President, Chief Digital Information Officer

#### Helio Pedro, MD

Section Chief, Genetic and Genomic Medicine

## **Faculty**

#### **MSK Faculty**

#### Andrea Cercek, MD

Section Head, Colorectal Cancer; Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers

#### Luis Diaz Jr., MD

Head, Division of Solid Tumor Oncology; Grayer Family Chair

#### Neil Iyengar, MD

Medical Oncologist, Exercise Oncology

#### Ross Levine, MD

Chair, Leukemia Research; Chief, Molecular Cancer Medicine Service; Deputy Physician-in-Chief, Translational Research

#### Pedram Razavi, MD

Director of Liquid Biopsy Technologies and Genomics

#### Greg Riely, MD

Vice Chair of Clinical Research, Department of Medicine

#### Zsofia Stadler, MD

Clinical Director, Clinical Genetics Service

#### Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Memorial Sloan Kettering Cancer Center and Hackensack Meridian Health. Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### **AMA Credit Designation Statement**

Memorial Sloan Kettering Cancer
Center designates this live activity
for a maximum of **4.00** *AMA PRA*Category 1 Credits™. Physicians should
claim only the credit commensurate
with the extent of their participation
in the activity.

# Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer
Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education.
Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible companies (commercial interests).
All relevant financial relationships have been mitigated prior to the commencement of the activity.

Relevant relationships with ineligible companies can be viewed online: mskcc.org/precisioncancer



## **Agenda**

7:30 ам	Registration and Breakfast		
8:30 am	Introduction and Welcome Andre Goy, MD David Pfister, MD		
8:45 ам	<b>KEYNOTE</b> Precision Interception: <i>Disease Prevention and Early Intervention at the Molecular Level</i> Luis Diaz Jr., MD		
9:15 ам	Immunobiomarkers: Lessons Learned from Rectal Cancer Andrea Cercek, MD		
9:35 ам	Break		
	NON-ACCRED	ITED SESSION*	
10:05 ам	<b>Impact and Potential of Liquid Biopsies in Oncology</b> Maher Albitar, MD		
10:25 ам	PANEL DISCUSSION Predicting Reponse to Immunotherapy; Liquid Biopsies - Use and Abuse		
	MODERATOR: Andre Goy, MD	PANELISTS: Maher Albitar, MD Andrea Cercek, MD Luis Diaz Jr., MD Jamie Koprivnikar, MD	
10:50 ам	Break		
1:20 AM	Interpreting Parallel Tu to Inform Diagnosis an Inherited Cancers Zsofia Stadler, MD	umor Normal Sequencing d Management of	
11:40 ам	Barriers in Access to Molecular Medicine John Marshall, MD		
12:00 рм	PANEL DISCUSSION Should Germline Data be Routinely Obtained to Complement Tumor Sequencing?; Lessons Learned in Molecular Medicine from Diverse Populations		
	MODERATOR: Martin Gutierrez, MD	PANELISTS: David (Kar Fai) Chow, MD Helio Pedro, MD John Marshall, MD	
		Zsofia Stadler, MD	

1:00 рм	KEYNOTE Clonal Hematopoeisis of Indeterminant Potential (CHIP): What We Know and What We Need To Ross Levine, MD		
1:30 рм	Using Molecular Data to Guide and Evaluate Healthy Living Programs: Lessons Learned from Breast Cancer Neil Iyengar, MD		
1:50 рм	PANEL DISCUSSION CHIP; Wellness in Cancer Care and Recovery		
	MODERATOR: David Pfister, MD	PANELISTS: Neil lyengar, MD David C. Leopold, MD Ross Levine, MD Renee Al-Sarraf, DVM	
2:20 рм	Break		
2:45 рм	<b>Big Data Studies as Tools to Advance Molecular Medicine</b> Andrew Ip, MD		
3:05 рм	PANEL DISCUSSION Opportunities and Caveats Regarding the Use of Big Data		
	MODERATOR: Andre Goy, MD	PANELISTS: Andrew Ip, MD Kash Patel, MD Pedram Razavi, MD Greg Riely, MD	
3:30 рм	Review of the Day/Closing Remarks Andre Goy, MD David Pfister, MD		
4:00 PM	Adjourn		

#### At the conclusion of this program, attendees will:

- appreciate how molecular data can be used to inform risk and guide interventions to prevent disease and improve outcomes.
- understand the potential utility and limitations of liquid biopsies.
- understand how germline data can complement tumor sequencing in cancer management.
- To learn how molecular data can complement healthy living programs.
- understand what clonal hematopoiesis of indeterminant potential is and its medical implications.
- appreciate how "big data" studies can be used to assess the impact of molecular medicine.

# mskcc.org/precisioncancer

#### **REGISTRATION FEES**

Residents, Fellows, and Trainees: \$25All Other Healthcare Providers: \$75

\*Please note this MSK CME event is non-refundable.

#### **DISCOUNTS/PROMOTIONS**

A registration discount is available for MSK Alumni and MSK Cancer Alliance to attend a MSK CME course. If you are a member of one of these groups, contact cme@mskcc.org for details.

Registration is complimentary for all **Hackensack Meridian Health employees**, however, you must complete registration through this website in order to attend. If you have not received a promotion code for complimentary registration, please contact cme@mskcc.org.

Registration is complimentary for all **MSK employees**; however, you must complete registration through this website in order to attend.

Please note that after your payment has been processed, no further promotional discounts or adjustments will be made to your registration.

For additional details and registration, visit: mskcc.org/precisioncancer



